Audit: QRS - L-Tyrosine for Health & Longevity

Audit conducted on 22/10/2026 13:43 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All lede, protocol, time-to-effect, benefit, gate, risk and monitoring content traces to ER passages (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications, Monitoring).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“(theoretical)”, “(theoretical for tyrosine)”, “(reduced effect)” and “appears to help” carried as in the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No claim strengthened or softened; MAOI kept as contraindication, “Caution”/”Monitor” classes preserved.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Facts kept in their ER categories (contraindications from the avoid list, interactions from interaction subsections, risk tiers from the risk section).
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names, NCT IDs or brand names in the QRS.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are ER labels/headings carried verbatim (e.g., monoamine oxidase inhibitors, phenylketonuria).
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede flags the older-adult dose signal relevant to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“not a proven longevity aid”; no “anti-aging” wording.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial terms (pill, by mouth, shot) found.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and Marker/Target/Why headers unchanged.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans present; marker_# expanded to 1–4, qualitative_item_# to 1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website spans, footer and template comments unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	No ER section is empty apart from High risks, which is handled by 13.5 (span hidden).
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Interaction, protocol, benefit, risk and qualitative labels use ER bold labels/headings; example lists trimmed only.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji; ER tier emoji and ⚠️ Conflicted markers removed.
4.5	The QRS is designed to render on one A4 page: every section is condensed to the shortest form the other checklist items allow, not extended onto a second page.	🟢	Content condensed; trailing rationales and citations stripped, example lists trimmed.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted (contains a colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.18 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1022-1317
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	10/22/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “a common dietary amino acid sold as a supplement for mental performance”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-list populations present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationales (e.g., “for whom safety data are lacking”) and citations stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	No parenthetical qualifiers in the ER contraindication bullets; “history of malignant melanoma” kept.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated; ER names avoid populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine non-contraindicated ER interactions present; MAOIs excluded as already a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Severity classes and theoretical qualifiers kept; each example list retains at least one ER example.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER interactions.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated; ER names interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Acute fixed dose, acute weight-based dose, daily low-dose approach.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides at least three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Onset 1–2 hours, duration about 3 hours, multi-month mood assessment.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Cognition (High) items first, mood (Low) last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three time-to-effect aspects available.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high span set to display: none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	TSH, free T4, plasma tyrosine and home blood pressure listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers listed.

Issues 22/10/2026 13:43

Pass rate 100.00%. No issues found.

Issues 22/10/2026 13:40

1. 4.5 — Untrimmed lists and optional clause: Key Interactions keeps full example lists for Thyroid medications (levothyroxine, liothyronine, methimazole) and Stimulants (methylphenidate, amphetamine salts, bupropion) at lines 555-556, and time_2_sub appends the optional clause “blood tyrosine neared baseline by 8 hours” at line 500; these could be shorter without breaking any other item.

Fixes 22/10/2026 13:40

1. 4.5 — Trimmed lists and optional clause: Trimmed the Thyroid medications examples to “levothyroxine, methimazole” and the Stimulants examples to “methylphenidate, bupropion”. Removed “; blood tyrosine neared baseline by 8 hours” from time_2_sub.

Issues 22/10/2026 13:37

1. 7.5 — Clinical term in lede: The At-A-Glance (QRS line 433) says “not a proven longevity intervention”; “intervention” is clinical-register vocabulary that a non-specialist would not use unprompted and should be replaced with a plain-language term.

Fixes 22/10/2026 13:37

1. 7.5 — Clinical term in lede: Replaced “not a proven longevity intervention” with “not a proven longevity aid” in the At-A-Glance; word count unchanged at 69.

Issues 22/10/2026 13:34

1. 7.2 — Conclusion bottom line missing: The At-a-Glance (line 433) covers only the first half of the ER Conclusion and omits its execution-relevant verdict that L-Tyrosine is “a low-cost, situational tool … with open questions about daily use, rather than a proven longevity intervention”.

Fixes 22/10/2026 13:34

1. 7.2 — Conclusion bottom line added: Rewrote the At-a-Glance (69 words) to add the ER Conclusion verdict, “looks like a situational tool, not a proven longevity intervention”, and that daily use remains uncertain; kept the intervention description, the older-adult dose signal and the tolerability statement.

Issues 22/10/2026 13:30

1. 4.5 — Redundant protocol and cadence text: action_1_sub (line 450) adds the redundant clause “morning or shortly before the planned demand” after “About 60 minutes before demanding mental work”, and monitoring_cadence (line 649) repeats “when combining with other stimulating compounds”, already stated in marker_4_why (line 642).

Fixes 22/10/2026 13:30

1. 4.5 — Redundant protocol and cadence text: Trimmed action_1_sub to “About 60 minutes before demanding mental work” and changed the cadence ending from “when combining with other stimulating compounds” to “of combined use”, relying on marker_4_why for the condition.

Issues 22/10/2026 13:26

1. 1.2 / 1.3 — Cadence drops practice hedges: The monitoring cadence (QRS line 649) presents the thyroid-panel and retesting schedule as fixed, omitting the ER’s “common practice” and “typically” qualifiers (ER Monitoring Protocol, lines 399-401), which strengthens a practice-based schedule.

Fixes 22/10/2026 13:26

1. 1.2 / 1.3 — Cadence practice hedges restored: Changed the monitoring cadence from “Thyroid panel … at baseline; for daily use, repeated … occasional users retested …” to “Common practice is a thyroid panel … at baseline; for daily use, typically repeated … occasional users typically retested …”, matching the ER wording.

Issues 22/10/2026 13:24

1. 1.3 — Age-dose claim loses scope: Protocol action_2_sub (line 461) reads “after 60, 100 mg/kg outperformed 150–200 mg/kg”, dropping the ER qualifier “on hard working-memory tasks” (ER Therapeutic Protocol, Age bullet) and so broadening the claim.

Fixes 22/10/2026 13:24

1. 1.3 — Age-dose claim scope restored: In action_2_sub, changed “after 60, 100 mg/kg outperformed 150–200 mg/kg” to “after 60, 100 mg/kg outperformed 150–200 mg/kg on hard working-memory tasks”, matching the ER Age bullet.

Issues 22/10/2026 13:20

1. 1.4 — Timing shown as target: Monitoring row 4 (line 639) puts “During the first week” in the Target column for blood pressure; that is the ER’s check timing (cadence), and the ER states no blood-pressure target.
2. 4.2 / 4.3 — Protocol labels abbreviated: The action labels (lines 444, 455, 466) drop the ER bold-label parentheticals “(cognitive-control protocol)”, “(military protocol)” and “(manufacturer protocol)”; the last loses that 500–1,500 mg daily is a manufacturer recommendation.

Fixes 22/10/2026 13:20

1. 1.4 — Blood-pressure target corrected: Changed marker_4_target from “During the first week” to “No target range given” and moved the first-week home blood-pressure check timing into the monitoring cadence.
2. 4.2 / 4.3 — Protocol labels restored verbatim: Restored the ER parentheticals in the action labels: “Acute fixed dose (cognitive-control protocol)”, “Acute weight-based dose (military protocol)”, “Daily low-dose approach (manufacturer protocol)”.